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Influence of zinc on glycosaminoglycan
neutralisation during coagulation
Ame´lie I. S. Sobczak, Samantha J. Pitt and Alan J. Stewart *
Heparan sulfate (HS), dermatan sulfate (DS) and heparin are glycosaminoglycans (GAGs) that serve as key
natural and pharmacological anticoagulants. During normal clotting such agents require to be inactivated
or neutralised. Several proteins have been reported to facilitate their neutralisation, which reside in platelet
a-granules and are released following platelet activation. These include histidine-rich-glycoprotein (HRG),
fibrinogen and high-molecular-weight kininogen (HMWK). Zinc ions (Zn2+) are also present in a-granules
at a high concentration and participate in the propagation of coagulation by influencing the binding of
neutralising proteins to GAGs. Zn2+ in many cases increases the aﬃnity of these proteins to GAGs, and is
thus an important regulator of GAG neutralisation and haemostasis. Binding of Zn2+ to HRG, HMWK and
fibrinogen is mediated predominantly through coordination to histidine residues but the mechanisms by
which Zn2+ increases the aﬃnity of the proteins for GAGs are not yet completely clear. Here we will
review current knowledge of how Zn2+ binds to and influences the neutralisation of GAGs and describe
the importance of this process in both normal and pathogenic clotting.
Introduction
Glycosaminoglycans (GAGs) including heparin sulfate (HS),
dermatan sulfate (DS) and heparins are key molecules involved
in several biological processes, including coagulation where
they play an important anticoagulant role.1 HS is mostly
synthesised by endothelial cells, where it lines the endothelium
and participates in its intrinsic anticoagulant properties.2 DS is
mostly synthesised in the sub-endothelium and is exposed to
plasma proteins during injury.3 Heparins are synthesised by
mast cells and may also be secreted following tissue injury,4,5
however, this has been disputed by some.6–8 The main rele-
vance of heparins are in clinical settings, where they and
heparin-based drugs are important agents used in the clinical
treatment of coagulatory disorders.9 As GAGs are physiologi-
cally found in a variety of sizes, heparin drugs are administered
clinically as unfractionated heparin (UFH), which have not
been cleaved or separated by size or as low molecular weight
heparin (LMWH), which are generally o8000 Da.10 All GAGs
exercise their anticoagulant activity through their binding
to serpins.1 The main partners for HS and heparin are anti-
thrombin (AT) and heparin cofactor II (HCII) while DS can only
bind to HCII.1 When bound together, the GAGs can change
the conformation of the reactive centre loop of the serpin to
increase the inhibitory activity of the molecule.11 During normal
coagulation, when clotting is required, anticoagulant GAGs
are neutralised by several proteins, including histidine-rich-
glycoproteins (HRG), high-molecular-weight kininogen (HMWK)
and fibrinogen.10,12
After iron, zinc is the most abundant transition metal in
the human body. Zinc is an important element in the body,
playing key structural and catalytic roles as well as functioning
as an extracellular and intracellular signalling molecule.
Ionic zinc (Zn2+) is essential for physiological processes such
as cell replication, tissue growth, immune functioning and
coagulation.13–15 The importance of Zn2+ is best illustrated by
the cases of zinc deficiency, which is defined as having a total
plasma zinc concentration below 0.7 mg L1 (normal range
is 0.8–1.0 mg L1).16–18 Zinc deficiency is associated with
coagulatory abnormalities including a reduced ability for
platelets to aggregate and longer bleeding times, which in
most cases can be quickly corrected by zinc supplementation
without secondary effects.16–18 In addition to the resting plasma
Zn2+ level, during coagulation platelets release Zn2+ stored
in their a-granules, thus initiating a signalling process.19–21
During this process Zn2+ acts to propagate several anticoa-
gulation pathways as well as both pro- and anti-fibrinolytic
pathways.13 In addition to Zn2+, platelet a-granules also release
numerous proteins that impact on coagulation, among which
are HRG, HMWK and fibrinogen.10,22 These proteins have both
the ability to bind Zn2+ and to bind and neutralise anticoa-
gulant GAGs.23–30 The mechanisms and impact by which Zn2+
influences GAG binding and neutralisation by these proteins is
reviewed here.
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Zn2+ repartition in plasma
Despite its requirement for various physiological processes,
Zn2+ is toxic at mid-high micromolar levels,31,32 therefore its
free/labile concentration is tightly regulated. The total con-
centration of Zn2+ in the plasma is approximately 20 mM.33
Those ions are mostly bound to serum albumin (75% of the
total Zn2+ concentration in the body, i.e. around 15 mM).33 The
remaining Zn2+ (around 5–6 mM) is bound to other proteins
such as a2-macroglobulin.
15,34 This fraction is regarded as non-
exchangeable as the binding is very tight.15,34 The remaining
Zn2+ is bound to small ligands and is considered ‘‘free’’ or
‘‘labile’’ because those ligands can easily be exchanged for
proteins or other ligands (more easily than when Zn2+ is bound
to serum albumin).15,34 The free Zn2+ concentration in plasma
is generally thought to be in the micromolar range, between
0.5 to 1 mM.15,34
The proportion of free/labile Zn2+ in plasma is dynamic
(Fig. 1). For example, during coagulation, Zn2+ is released from
platelets.35,36 Healthy platelets accumulate around 35 g L1 of
Zn2+ that they sequester into two pools, the cytoplasm (around
60% that is used to regulate platelet function)21,37 and the
a-granules (around 40%).21 Variations of the total amount of
Zn2+ present in the plasma aﬀect the quantity present in the
platelets, as well as the distribution of the two pools.37 There is
still some uncertainty as to how Zn2+ is incorporated into the
platelets. Some Zn2+ may be incorporated when the Zn2+-bound
fibrinogen-coagulation factor XIII(a2) complex enters the platelet
through binding to fibrinogen receptors.37 However the main
mechanism for Zn2+ entry into platelets is likely to be through
Zn2+ transporters (as reviewed by Taylor and Pugh);38 the exact
mechanism however remains to be elucidated. When platelets are
activated, up to half of the a-granule Zn2+ pool is released.35,36
This action has been reported to increase the labile/free plasma
Zn2+ concentration to 7–10 mM in the proximities of activated
platelets.35,36 The resultant increase in Zn2+ concentration can
then facilitate its binding to coagulatory proteins and in-turn
alter their affinity for other proteins or ligands to influence the
coagulation process.19,20 Platelets are not the only cells in the
blood that store Zn2+. Indeed, neutrophils, lymphocytes and
erythrocytes all contain Zn2+ (reported levels of total zinc are
105 mg/1  1010 cells, 116 mg/1  1010 cells and 41 mg g1
haemoglobin, respectively)39 and may therefore release Zn2+
under certain circumstances in a manner similar to platelets
(such as at sites of injury, although this has yet to be confirmed).
In addition, the epithelium contains around 60 mg Zn2+/g of dry
weight,40 and epithelial cells release some of this when damaged
(the exact amount is not known).41
Relevance of Zn2+ in coagulation
control
For a long time, the role of Zn2+ in coagulation had been ignored
and was likely often masked by the use of citrate as an anti-
coagulant during blood collection (with citrate forming com-
plexes with metallic cations). However, in more recent years,
the importance of Zn2+ in coagulation and regulation of platelet
function has started to emerge.13,38,42 A variety of blood proteins
involved in coagulatory processes have been identified as
Zn2+-binding proteins. In many cases the ability to bind Zn2+
has the potential to influence their activities and impact
Fig. 1 Coagulation control by glycosaminoglycans and Zn2+. (A) Anticoagulant glycosaminoglycans bind to antithrombin and enhance its neutralisation
of thrombin (and/or factor Xa). (B) When platelets become activated, the Zn2+ released from the a-granules of platelets bind to the GAG neutralising
proteins, increasing their aﬃnity for GAGs and allowing them to neutralise them. Once neutralised, the GAG cannot promote the inhibition of thrombin
and clotting occurs. (C) Sources of Zn2+ in plasma. During coagulation, Zn2+ is released by activated platelets. However, erythrocytes, lymphocytes and
neutrophils contain Zn2+ which may be released under certain conditions. In some disease states, elevated levels of free fatty acids may also influence
available Zn2+ levels through release from serum albumin. Atherosclerotic plaques contain up to six time more Zn2+ than healthy tissue and could
potentially release Zn2+ when they rupture. The structure of human serum albumin (with stearate bound) was taken from PDB 1E7I.109
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upon haemostasis. When looking at specific interactions, Zn2+
has been marked as an initiator of the contact activation
pathway of coagulation through enhancing the interactions of
contact proteins with polyanionic surfaces and their assembly
on endothelial cells and platelets.13 Zn2+ enhances platelet
aggregation and activation by increasing internal platelet
signalling and external binding of platelets to their ligands.13
It also enhances fibrin formation while also attenuating throm-
bin activity.13 Simultaneously, Zn2+ is also a regulator of the
anticoagulant and fibrinolytic pathways. It can inhibit platelet
activation by increasing HMWK and factor XII competition with
thrombin to bind GPIb on platelet surface. Zn2+ also attenuates
FXa generation by FVIIa, both increases and reduces fibrino-
lysis and modulates the activities of protein C, protein S and
heparin-mediated anticoagulant pathways and the pro- and
anti-coagulation activities of HRG.13
Many of the studies examining the impact of Zn2+ on
coagulation have utilised purified protein systems where zinc-
buﬀering or binding molecules normally found in plasma are
absent. Therefore, it is not clear in some cases whether the
labile Zn2+ concentrations used are physiologically (or patho-
physiologically) attainable. With the involvement of Zn2+ in so
many aspects of the clot process, it is diﬃcult to tease out in
which Zn2+ may be most involved. Dietary Zn2+ has been shown
to exert a pronounced eﬀect on platelet aggregation in humans
and rats.16–18 Several studies have also investigated correlations
between Zn2+ concentrations and clot formation and lysis.
Generally, Zn2+ enhances clotting but reduces lysis – specific
effects include an increase in fibrin diameter and clot porosity
and reductions in clot stiffness.36,43 Yet, those studies were
realised after dialysing the plasma and adding back Zn2+, a
process which may have altered the concentration of certain
(likely smaller) molecules that influence clotting.
Zn2+ binding by anticoagulant GAGs
HS, DS and heparin are highly negatively-charged; thus their
binding to other proteins mainly occurs through electrostatic
interactions.44 This type of interaction will increase with the
degree of sulfation of the GAGs. HS is generally less sulfated than
heparin but more so than DS. Metal ions are important binding
partners of GAGs and, in plasma, both Ca2+ and Zn2+ have been
shown to coordinate to them.21 Seo, Schenauer and Leary revealed
that the binding of metal ions to a heparin octasaccharide,
including Ca2+, Mn2+, Co2+, Fe2+ and Ni2+, triggers conformational
changes that have the potential to aﬀect their interactions with
their ligands.45 The eﬀect of Zn2+ was not examined in their study
but is likely to mimic the eﬀects of these other metal ions. As both
Ca2+ and Zn2+ are released from platelets during coagulation and
participate in the regulation of coagulation, this is of particular
interest as it is likely that this mechanism alters the anti-
coagulant activities of heparin and HS following platelet
activation.21 UFH has been shown to bind Zn2+ via two diﬀerent
mechanisms: the first represents a high-aﬃnity form of binding
(the equilibrium constant is 976 M1) whilst the second is a
low-aﬃnity form of binding that only occurs at high Zn2+ con-
centrations (the equilibrium constant is 241 M1).46 Both binding
events are entropy driven and both involve sulfated side chains on
the GAGs. The exact stoichiometry of these binding events has not
yet been precisely defined but it is assumed that the first mode of
binding involves one zinc ion binding per disaccharide and that
the second mode intervenes only after saturation is reached for
the first one.46 GAGs interact with basic amino acids on proteins,
generally lysine and arginine side-chains that are not normally
aﬀected by the presence of cations.47 Those cations however often
bind to exposed histidines, which are positively charged, and this
binding may then facilitate the binding of the protein to GAGs by
reducing the electrostatic repulsion between the two of them.47
As Zn2+ is released at the beginning of the coagulation process,
its eﬀect on GAG neutralisation reduces anticoagulation and
promotes clotting.
Impact of Zn2+ on protein–GAG
interactions
Numerous proteins in plasma have the ability to neutralise
anticoagulant GAGs, as reviewed previously.10 Among them, three
are known to bind Zn2+: HRG,28 HMWK29 and fibrinogen.27
However, the Zn2+ binding properties of all GAG-neutralising
proteins have not been examined and there are probably more
that possess this ability. This ability to bind Zn2+ is important as
Zn2+ has the potential to influence GAG binding and neutralisa-
tion by those proteins (Fig. 1). HRG, HMWK and fibrinogen are
stored in platelet a-granules alongside Zn2+ and are therefore
released together during coagulation. All three proteins are
synthesised in the liver and, in addition to being stored in
platelets, they are present at high nanomolar to low micromolar
concentrations in plasma (1.3–2.0 mM for HRG,48,49 1–2 mM for
HMWK50 and 12–24 mM for fibrinogen).51 Their specific roles in
coagulation are diverse. Fibrinogen plays a prominent role as
when it is cleaved, it polymerises to form fibrin clots.52 HRG plays
a regulatory role by inhibiting fibrinolysis in addition to being
incorporated in blood clots,53 while HMWK is a key activator of
the contact activation pathway of the coagulation cascade.54 Thus
all three proteins are in contact with endothelial GAGs and are
likely to be important for GAGs neutralisation during coagula-
tion. This section will examine the Zn2+ and GAG binding proper-
ties of these three proteins and how Zn2+ can influence GAG
neutralisation.
Histidine-rich glycoprotein (HRG)
HRG is a single chain protein composed of several structural
domains that include a histidine-rich region (HRR). This region
is important in both proteins, as neutrally-charged histidine
residues bind Zn2+ via their imidazole side chains.28,48 HRG also
contains two cystatin-like domains at its N-terminus (N1 and N2)
and possesses a C-terminal domain, whilst its histidine-rich
region is flanked by two proline-rich regions (Fig. 2).55 The
structure of HRG has not yet been fully resolved. A crystal
structure of the N2 domain has been reported (PDB: 4CCV),56
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but structural information relating to the other domains
(including the Zn2+-binding HRR) is lacking. Nevertheless,
Human HRG has been demonstrated to bind up to 10 Zn2+ ions
with an average Kd of 6.13 mM.
48,57 Current evidences suggest
that there are no clearly defined preferential binding sites for
Zn2+ on HRG.58 When the net charge of HRG becomes positive,
either through a change in protonation of the histidine residues
(through a change in pH) or through binding of those residues to
metal cations, the conformation of the molecule changes, influ-
encing its aﬃnity for binding its ligands.19,48,58–62
HRG binds heparin with a Kd of 32.9 nM in the absence of
Zn2+ and 5.1 nM in the presence of 1 mM Zn2+.57 Isothermal
titration calorimetry studies have shown that there are two
diﬀerent modes of heparin binding, which are thought to occur
at diﬀerent binding sites.57 The first mode is Zn2+-dependent
and thus most likely involves binding at the HRR.57,63 As Zn2+
only influences the binding of long chain heparins,57 this first
binding site only involves long chain heparins (Z10 kDa).57,64
The second mode of binding is not dependent on chain length
and is thought to occur at the N1 and N2 domains,20 although
the exact location of this site is still unknown. The aﬃnity
of the second mode of binding is not directly aﬀected by the
presence of Zn2+, but Zn2+ binding to the HRR may induce
conformation changes in HRG that would make this site more
accessible to heparins. HRG forms mainly 1 : 1 complexes with
heparin, but it can form 2 : 1 complexes with longer chain
heparins in the presence of Zn2+.64 HRG has been shown to
neutralise heparin in plasma with this ability (like binding) also
dependent on the size of the heparin; with longer-chain heparins
having a higher aﬃnity for HRG.65 For example, even excess ratio
of 500 : 1 HRG :heparin octasaccharide can neutralise less than
half of the ability of heparin to accelerate the inactivation of
factor Xa by AT.65 Zn2+-Dependent heparin binding by HRG only
occurs when Zn2+ is released from activated platelets; otherwise,
the metal concentration is too low and heparin preferentially
binds the AT-thrombin complex.66 HRG can neutralise heparin-
mediated thrombin inhibition by both AT and HCII, but it is
much weaker in neutralising DS-mediated thrombin inhibition
by HCII.67–69 HRG can also bind and neutralise HS in a Zn2+-
dependent-manner.70 Thus, HRG is an important anticoagulant
GAG neutraliser in plasma and this neutralisation is dependent
upon the plasma Zn2+ concentration.
High-molecular weight Kininogen (HMWK)
HMWK is a single chain protein that consists of 6 domains, one
of which, domain 5, contains a HRR (Fig. 3).54 Kallikrein cleaves
domain 4 of HMWK, releasing bradykinin and another peptide,
while the rest of the protein forms a two chain HMWK, with the
heavy chain being the N-terminal section composed of domain
1, 2 and 3 and the light chain being domain 5 and 6. Both
chains are then linked together by a single disulfide bond.54
Like HRG, HMWK has not yet been fully crystallised and so the
Zn2+ binding domain is also not fully characterised. It is known
that Zn2+ binds mainly to histidine residues of the HRR located
between the residues Gly440 and Lys458 of domain 5. Zn2+
binding is known to induce a conformational change in this
domain.71 The aﬃnity and stoichiometry of Zn2+ binding by
HMWK have not yet been determined despite its potential to
influence the binding of HMWK to its ligands.
Like HRG, HMWK binds heparin in a Zn2+-dependent
manner.25 The intact form of HMWK binds heparin with higher
aﬃnity than the cleaved form of the protein (the Kd values of
intact and cleaved forms are 2.1 nM and 14.2 nM, respec-
tively).29 The presence of 50 mM Zn2+ increases the binding
aﬃnity even further (Kd = 0.30 nM for intact HMWK).
29 Heparin
binds to the light chain portion of HMWK, at the HRR, in
domain 5, which is known to mediate HMWK-binding to
negatively-charged surfaces.25,29 Within this domain the bind-
ing of GAGs occurs at a combination of diﬀerent sites, some of
which are sensitive to Zn2+.29,47 In addition to histidines, this
region is rich in lysine residues, which are involved in heparin
binding.29,47 The heparin binding aﬃnity of HMWK increases
when the pH decreases and the histidine residues become
protonated, regardless of the presence of cations.25 UFH and
LMWH bind with similar aﬃnity to HMWK in the absence of
Zn2+ but the influence of the heparin chain length on the
binding aﬃnity in the presence of Zn2+ is not yet known.25
HMWK competes with AT, thrombin or the AT-thrombin
complex for heparin-binding and can neutralise the anticoagu-
lant eﬀect of heparin in plasma.25 However, this binding may
not be specific, as HMWK can bind all heparins regardless of
whether or not they possess the saccharide sequence used to
bind AT with high aﬃnity, and thus several HMWK molecules
may be required to fully neutralise one heparin molecule.25
Maximal neutralisation has been shown to occur in the pre-
sence of 10 mM Zn2+.25 In addition, HS proteoglycans located at
the cell surface can bind HMWK in a Zn2+-dependent manner
but the eﬀect of this binding on the anticoagulant activity of HS
has not been investigated directly.50 Thus HMWK appears to
neutralise anticoagulant GAG in a similar manner to HRG.
As HMWK is present in plasma at similar levels to HRG and
binds heparin with similar aﬃnity (Kd in low nanomolar range),
Fig. 2 Structure of histidine-rich glycoprotein. N1 and N2 are N-terminal
domain 1 and 2, they have a GAG binding activity; PRR1 and PRR2 are
proline-rich regions; HRR is the histidine rich region that binds Zn2+ and
GAG; C is the C-terminal domain.
Fig. 3 Structure of high-molecular-weight kininogen. Domains 1, 2 and 3
are cystatin-like domains, with 2 and 3 having a cysteine protease inhibitor
activity; domain 4 is bradykinin and another peptide; domain 5 is the
surface-binding domain containing the histidine-rich region that binds
GAGs and Zn2+; domain 6 is the domain binding prekallikrein and activated
coagulation factor XI.
Critical Review Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
on
 8
/2
8/
20
18
 3
:3
1:
21
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2018 Metallomics
these proteins may be of equal importance in anticoagulant
GAG neutralisation.
Fibrinogen
Fibrinogen is a homodimer composed of two sets of three
diﬀerent polypeptides chains, Aa, Bb and g (Fig. 4).72 Most of
the protein has been crystallised to some extent, with the excep-
tion of the highly variable aC domain (PDB 3GHG).73 Fibrinogen
binds Zn2+ at two diﬀerent regions. The first set of binding sites is
located in the D-domains (Fig. 4, insert 1) and has a stoichio-
metry of six (three ions per D-domain).74 The sites predominantly
consist of histidine residues located on the g chain, with His-g217
and His-g234 thought to be involved,74 however the eﬀect of Zn2+
binding at this region on the conformation of the protein is
unknown. Another Zn2+-binding region has been identified in the
aC-domain and also involves histidine residues (His-a544
and His-a545).75 Binding of Zn2+ to this region is thought to
induce a change in the conformation of the protein.75 Based on
several studies, Zn2+ binding to fibrinogen has an average Kd of
B1–18 mM, but the individual contributions of the two groups
of sites are unknown.27,36,75
Two diﬀerent heparin binding modes have been identified
on fibrinogen. The first occurs at a site located on the b chain in
the E domain around the Bb1-57 region (Fig. 4, insert 2). It has
been shown that a synthetic peptide corresponding to this exact
region binds heparin with a Kd of 16.5 mM,
76 whilst a dimer of
the peptide, (Bb1-66)2 exhibits an almost two orders of magni-
tude higher aﬃnity for heparin (Kd of 210 nM), compared to
the monomer.76 As this Kd value is close to the Kd of intact
fibrinogen (228 nM), this suggests that the binding of heparin
to fibrinogen occurs predominantly via this binding mode and
that the dimeric structure of fibrinogen plays an essential role
in this binding.76 A second heparin-binding mode occurs when
Zn2+ binds to the aC domains of fibrinogen.75 Binding of Zn2+ is
thought to induce a change in the conformation of the protein
promoting heparin-binding to the nearby E domain.75 In presence
of 12.5 mM Zn2+, the average Kd for heparin binding to fibrinogen
is 60 nM.75 This represents a 4-fold increase in aﬃnity, contrast-
ing to a lower aﬃnity (Kd of 539 nM) for fibrinogen without the aC
domain in the presence of Zn2+.75 The link between heparin chain
length and binding aﬃnity in the presence and absence of Zn2+ is
not yet known. The binding of fibrinogen to heparin participates
in the neutralisation of its anticoagulant activity. The direct study
of fibrinogen-mediated GAG neutralisation has been complicated
by the fact that thrombin cleaves fibrinogen. However, fibrinogen
has been shown to be more eﬀective at neutralising DS than HRG
(and platelet factor 4).68 This neutralisation occurs at physio-
logical fibrinogen concentrations and is not aﬀected by the size
or the degree of sulfation of DS.68 The mechanism of neutra-
lisation appears not to occur through direct competition with
Fig. 4 Structure of fibrinogen. The protein forms hexamer made of three diﬀerent strands (Aa Bb g)2. All of the N-terminals are in the E domain which is
the heparin binding domain. The three strands then coil together until they reach the D domains where the C-terminal of the b and g strands are located.
This domain is a Zn2+-binding domain. The a strand goes back toward the E domain where its C-terminal forms the aC domain, another Zn2+ binding
domain. Insert 1. Crystal structure of fibrinogen D domain (one of the Zn2+ binding domain) and part of the coil–coil region (PDB structure 3GHG).73 The
histidine residues which have the potential to be involved in Zn2+ binding are represented in pink with the residues His217 and His234 known to be
involved represented in yellow. Most of those residues are hidden beneath the surface of the protein. Insert 2. Crystal structure of fibrinogen E domain
(the heparin binding domain) and part of the coil–coil regions, (PDB structure 3GHG).73 The positive charges are represented in blue and the negative
charges in red. The Lys and Arg residues which usually constitutes the main binding partners of GAGs are represented in green. The first few residues of
the Bb chain are mobile and so they are not visible in the crystal structure, with b58 the first residue that can be observed (represented in yellow). This
residue is a protruding Lys that is believed to be important for GAG binding. As the GAG binding affinity of fibrinogen is enhanced when the protein is
converted into fibrin by cleavage of the A and B peptides, the absence in the crystal structure of the first few residues of the Bb chain may be the reason
for exposure of the b58 residue. The aC domain is attached to the E domain; binding of Zn2+ ions to its His a544 and His a545 is thought to change the
conformation of the protein and thus facilitate GAG binding to the E domain.
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the thrombin–HCII complex for DS binding but by controlling
the rate of formation of this complex.68 In addition, fibrin can
also form complexes with heparin, AT and thrombin to reduce
thrombin inhibition by AT in a Zn2+-dependent manner.52,77
Thus, fibrinogen is an important anticoagulant GAG neutrali-
ser, with the plasma concentration of fibrinogen being linked
to heparin resistance in patients.78 The sensitivity of fibrinogen
toward plasma Zn2+ levels relative to HRG and HMWK is not
yet known.
Other anticoagulant GAG neutralising proteins
Zn2+ can also potentially aﬀect the neutralisation of antic-
oagulant GAGs through, fibronectin, fibroblast growth factors
(FGF), FGF-1 and FGF-7 and activated coagulation factor VII
(FVIIa).30,79,80 Fibronectin can be found as the alternative spliced
forms of cellular or plasma fibronectin. Plasma fibronectin is
present in plasma at a concentration of 300–600 nM and is also
stored in platelet a-granules and released during coagulation.81
Cellular fibronectin is synthesised by endothelial cells and can be
released into plasma during wound healing.82 Zn2+ binding by
fibronectin has not yet been fully characterised, however several
regions have been shown to bind Zn2+ in vitro. These include the
collagen/gelatin binding domain (binding to which has been
shown to elicit a conformational change in this region),30,83,84
the cell binding domain30 and the alternatively spliced type III
connecting segment (IIICS) which is only fully present in cellular
fibronectin and a small fraction of plasma fibronectin.85 It is still
unclear whether plasma fibronectin binds Zn2+ physiologically or
whether this only occurs with cellular fibronectin.85,86 Consider-
ing that Zn2+ induces a conformational change in the protein and
may thus influence GAG binding, this is an important question to
answer. Fibronectin possess 5–6 ionic GAG binding sites.26,81 The
first binding site (often termed Hep1) is found in the N-terminal
region. As Zn2+ binding to the neighbouring gleatin-binding
region induces a conformation change in the protein, it is
probable that this could impact on GAG binding in Hep1.83
The second GAG binding region (Hep2) has two distinct GAG
binding sites and constitutes the high affinity GAG binding
region.87 As the region is flanked by two Zn2+-binding regions,
the cell-binding region and the IIICS, Zn2+ binding may also
impact on GAG binding at this site. The global Kd of heparin
binding to fibronectin is 0.9 mM for a 18–20 saccharide heparin
(molecular weight 6000 Da).87 The affinity for UFH is not yet
known. Fibronectin does interfere with AT binding to immobi-
lised heparin as a function of heparin concentration. However
AT is only completely displaced from heparin at fibronectin/AT
ratios higher than are found physiologically.81 Fibronectin also
binds HS and DS but its effect on their neutralisation is not
known.88,89 Thus plasma Zn2+ levels have (at least in theory) the
potential to influence GAG binding and neutralisation by
fibronectin. This means that fibronectin has the potential to
strongly react with the Zn2+ released during coagulation and to
be major GAG-neutralisers during this time.
Fibroblast growth factors are present at very low concentrations
in plasma (ca. 28–48 pM for FGF-1 and 643 pM for FGF-7),90,91
nevertheless they are normally attached to GAGs of the endothelial
surface layer and depend on this binding to exert their functions
(including oligomerisation, binding to their cognate receptors
and transport between cells).92 They are therefore important
binding partners for GAGs. FGF-1 and FGF-7 bind UFH with Kd
values of 29 nM and 140 nM, respectively.93 DS also interacts
with FGF-7 and FGF-1 but with lower affinity than heparin and
HS. FGF-7 and to a lesser extent FGF-1 have been shown to
neutralise UFH.94 Unlike with HRG, HMWK and fibrinogen,
the affinity of these interactions are reduced by the presence
of metal ions (Na+, K+, Ca2+, Cu2+ and Zn2+).93 However, it is
unknown whether metal ion binding influences the neutralisa-
tion of the GAG. It is possible that binding of metal ions by these
FGFs is a mechanism to facilitate their release from the endo-
thelium when the plasma concentrations of those ions are
elevated. Nevertheless, FGF-1 and FGF-7 are unlikely to be impor-
tant GAG neutralisers in vivo due to their low plasma levels.
FVIIa is a coagulatory protein involved in the contact activa-
tion pathway.79,80 It binds UFH with a Kd value of 3.38 mM in a
Ca2+-dependent manner.95 FVIIa possesses two Zn2+ binding
sites but it is not yet known if binding of Zn2+ plays any role in
heparin binding.96 FVIIa can neutralise both UFH and LMWH,
but its eﬀects on HS and DS have not yet been studied. However,
like FGF-1 and FGF-7, FVIIa is only present at a low concentra-
tions in plasma (ca. 16 nM)97 and therefore it is not likely to be as
relevant in anticoagulant GAG neutralisation as the proteins
listed above. Nevertheless, the interaction of Zn2+ with HRG,
HMWK and fibrinogen shows that Zn2+ is an important regulator
of GAG binding and neutralisation by plasma protein and it is
therefore important to investigate whether Zn2+ has the same
eﬀect on other GAG neutralising proteins.
Clinical significance of Zn2+-induced
GAG neutralisation
In addition to being released during injury by epithelial cells
and platelets, plasma Zn2+ levels are also increased in certain
disease states (Fig. 1). Indeed, atherosclerotic plaques are also
known to contain up to six-times more Zn2+ than healthy tissue.98
However, only total Zn2+ concentration has been measured and
so the concentration of labile Zn2+ is not clear. The increase in
Zn2+ concentration in atherosclerotic plaques correlates with an
increase in Ca2+ concentration.98 In addition, both metal ions are
present at high levels in areas of plaque mineralisation.99 This
may signify that the accumulation in both metals occurs through
a common mechanism that has not yet been identified.
Accumulated Zn2+ could be released into the blood during
plaque rupture, thus participating in the pro-thrombotic nature
of these events.
The concentration of available Zn2+ is also directly influ-
enced by the plasma free fatty acid (FFA) levels. Serum albumin
is the main plasma carrier for both Zn2+ and FFAs.57,100 When a
FFA molecule binds at a high aﬃnity binding site (called the
FA2 site) adjacent to the main Zn2+ binding site, an allosteric
interaction leading to perturbation of the Zn2+ binding site
occurs. In healthy individuals around 75% of total plasma Zn2+
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(around 15 mM) is bound to serum albumin and so this
mechanism may result in the release of up to 15 mM Zn2+ in
plasma in individuals with elevated FFA levels (when those
levels are elevated enough to completely prevent Zn2+ binding
by serum albumin). In certain conditions, the concentration of
FFA can increase by up to six times: in diabetes FFA concen-
trations have been reported to be 0.62–0.82 mM in men and
0.82–0.98 mM in women (compared to controls of 0.59–0.68 mM
for men and 0.74–0.83 mM for women).101 In non-alcoholic fatty
liver disease, the corresponding concentrations are 0.12–3.4 mM
(compared to controls of 0.11–0.9 mM).102 In obesity, FFA
concentrations are 0.56–1.15 mM (compared to controls of
0.28–0.89 mM).103 Elevated FFA levels are also associated with
some cancers; in malignant lymphoma FFA concentrations
were found to be 0.55–1.8 mM (no controls);104 All of these
conditions are associated with a higher incidence of developing
thrombotic complications.105,106 In addition, under hyper-
glycemic conditions, serum albumin can undergo non-enzymatic
glycation reactions which can disrupt the protein conformation
and also directly affect its main Zn2+-binding site.107 This is
another mechanism by which diabetic state can affect Zn2+
transport and speciation.
Another condition that may be associated with altered
plasma Zn2+ homeostasis is analbuminemia (albumin deficiency),
which is defined as having a plasma albumin level of o1 g L1.
In total, 78 cases have been reported in the analbuminemia
register (www.albumin.org) and the prevalence of the disease is
estimated to be less than 1 in 1 million.108 Individuals with
analbuminemia have been reported to have elevated levels of
other plasma proteins, including coagulation factors, as a
compensatory mechanism.108 It is thought that those proteins
take up most of the functions of albumin and therefore it is
unclear if Zn2+ transport in plasma is aﬀected or not. However,
it has been shown that Ca2+ and Fe2+ have an altered protein-
binding profile in these individuals.108 The transport of FFA is
taken up by apolipoprotein B-100 and so FFA levels are close to
normal (but dyslipidaemia is present).108 Follow-up studies of
patients with analbuminemia have been limited, which limits
the report of complications. Nevertheless, such follow-up
studies have included reports of atherosclerosis and hyper-
coagulability in these individuals,108 but it is not clear if this
may be due to alterations in plasma Zn2+ level/speciation or
changes in plasma coagulatory protein levels.
The impact of Zn2+ on anticoagulant GAG-neutralisation is
useful to consider, specifically as this process impacts on
thrombin activation, an event that directly aﬀects both platelet
aggregation (through binding to cell surface receptors) and fibrin
clot formation (through cleavage of fibrinogen). Indeed, by
enhancing the neutralisation of the GAG present in the endo-
thelium surface layer, Zn2+ induces a change in the natural
anticoagulant properties of the endothelium.10 When coagula-
tion is needed, this participates in the promotion of clotting.
However, if Zn2+ speciation is chronically altered, such as is
likely in certain diseases states (atherosclerosis, diabetes, obesity
and cancer), then this could aﬀect anticoagulant processes in the
endothelium resulting in a pro- or hyper-thrombotic state
through enhanced GAG neutralistaion.10 This phenomenon
could also directly aﬀect the eﬃciency of heparin-based treat-
ments, which are widely used during surgeries and to manage
thrombotic complications.10 In order to confirm this, it would be
interesting to measure plasma Zn2+ levels in patients undergoing
heparin treatment and to compare it to their response to this
treatment. If such a relationship is confirmed then an option
may be to control Zn2+ levels in those patients rather than to
switch to another anticoagulant treatment whose eﬃciency
could also be potentially aﬀected by Zn2+.
Conclusion
Zn2+ plays a major role in the regulation of coagulation that
is only starting to be understood. Because of this role, Zn2+
homeostasis in platelets and its speciation in plasma are
especially relevant to the understanding and treatment of blood
diseases. In particular, they can aﬀect GAG binding and neutra-
lisation by the platelet-stored proteins HRG, HMWK and fibrino-
gen. This mechanism is relevant to healthy coagulation processes
through the natural anticoagulation properties of the endo-
thelium, but also in anti-thrombotic treatments. Indeed, it may
partly explain the observed variability in dose response to
heparins and heparin-based drugs. This implies that free plasma
Zn2+ levels need to be monitored in individuals with coagulatory
disorders or at-risk of thrombotic events. The control of free
plasma Zn2+ levels may also be a treatment lead for individuals
suﬀering from high levels of plasma FFA who are at high risk of
thrombotic disorders.
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